TRT and High Hematocrit: Does “Thick Blood” Really Mean Blood Clots?
If you have been on testosterone replacement therapy for any length of time, you may have heard some version of this:
“Your hematocrit is high. Your blood is getting too thick.”
Sometimes the next sentence is even more alarming:
“You could get a blood clot.”
There is some truth behind the concern. Testosterone can increase red blood cell production, and hematocrit is one of the most important laboratory values we monitor during testosterone therapy.
But the phrase “thick blood” often creates more fear than understanding.
A hematocrit of 52% or 53% does not mean a blood clot is forming inside your body. TRT-induced erythrocytosis is also not the same disease as polycythemia vera, a bone-marrow disorder with its own biological mechanisms and substantially different thrombotic risk.
At the same time, progressively increasing hematocrit should not simply be ignored.
The right answer lies somewhere between those two extremes.
Let’s break down what hematocrit actually measures, why testosterone raises it, what the evidence says about blood clots, and how I approach an elevated hematocrit in men receiving testosterone therapy.
What Is Hematocrit?
Your blood contains several components:
Plasma
Red blood cells
White blood cells
Platelets
Hematocrit is the percentage of your blood volume occupied by red blood cells.
For example, a hematocrit of 48% means approximately 48% of the measured blood volume consists of red blood cells.
Testosterone stimulates the production of red blood cells. Consequently, increases in hemoglobin and hematocrit are among the most predictable effects of testosterone therapy.
In fact, the American Urological Association describes increased hemoglobin and hematocrit as the most frequent adverse effect associated with testosterone treatment.
That does not necessarily mean testosterone is doing something pathological.
Testosterone is stimulating a normal physiologic pathway.
The question becomes:
How much of an increase is acceptable?
Why Does Testosterone Increase Hematocrit?
Testosterone stimulates erythropoiesis—the production of red blood cells—in several ways.
One appears to involve erythropoietin, or EPO, a hormone primarily produced by the kidneys that signals the bone marrow to produce red blood cells.
Testosterone can initially increase EPO and establish a new relationship between erythropoietin and hemoglobin.
Testosterone also decreases hepcidin, an important regulator of iron metabolism. Lower hepcidin makes more iron available for red blood cell production.
In simplified terms:
Testosterone → increased erythropoietic signaling → greater iron availability → increased red blood cell production → higher hemoglobin and hematocrit.
This biology is one reason testosterone can actually be beneficial in appropriately selected hypogonadal men who are anemic.
But the same pathway can sometimes push hematocrit higher than we want it.
A recent review describes testosterone-induced erythrocytosis as involving changes in EPO, hepcidin and the body’s hemoglobin regulatory “set point.”
Erythrocytosis Is Not the Same Thing as Polycythemia Vera
This distinction matters enormously.
The words polycythemia and erythrocytosis are sometimes used interchangeably in everyday clinical conversation.
But they do not necessarily describe the same biological condition.
Polycythemia vera
Polycythemia vera is a myeloproliferative disorder—a bone-marrow disease in which blood-cell production becomes abnormal.
Patients with polycythemia vera can have substantial thrombotic risk for reasons extending beyond simply having a high hematocrit.
TRT-induced erythrocytosis
Testosterone-associated erythrocytosis is generally a secondary increase in red blood cell production caused by testosterone’s effect on normal erythropoietic pathways.
These are not biologically identical conditions.
That distinction matters because much of the historical fear surrounding elevated hematocrit originated from conditions such as polycythemia vera.
We should therefore be careful about assuming that every hematocrit of 52%, regardless of its cause, carries exactly the same risk. A contemporary review specifically highlights the important physiological differences between primary erythrocytosis such as polycythemia vera and secondary erythrocytosis caused by testosterone.
But Doesn’t Higher Hematocrit Make Blood Thicker?
Yes—to a degree.
As hematocrit increases, blood viscosity also increases.
That is physiologically real.
But this is where an important distinction is often lost:
Increased viscosity does not automatically equal thrombosis.
Blood clotting is extraordinarily complicated.
Venous thromboembolism is influenced by factors including:
Genetics
Previous DVT or pulmonary embolism
Smoking
Obesity
Cancer
Immobilization
Surgery
Inflammation
Certain medications
Thrombophilias
Age
Cardiovascular disease
And potentially hematocrit
So the question isn’t:
“Does hematocrit affect viscosity?”
It does.
The more useful question is:
“At what hematocrit does TRT-induced erythrocytosis meaningfully increase clinical events?”
That answer is less certain.
What Does the Research Actually Show About Blood Clots?
This is where the story gets interesting.
Large randomized testosterone trials and meta-analyses have generally not demonstrated a clear dramatic increase in thromboembolic events from properly managed testosterone therapy.
A systematic review and meta-analysis examining testosterone and vascular thromboembolic events found no clear overall increase in thrombosis attributable to testosterone therapy, although the available trials have important limitations for studying relatively uncommon events such as VTE.
The large TRAVERSE cardiovascular safety trial also did not demonstrate an association between change in hematocrit and major cardiovascular events or venous thromboembolism in its hematocrit analysis.
But there is an important caveat:
Patients in clinical trials are monitored.
Doses get adjusted.
Men with substantially elevated hematocrit may be excluded or have therapy stopped.
That is very different from someone receiving poorly monitored testosterone for several years with hematocrit climbing unchecked.
The 52% Study We Should Pay Attention To
One of the most useful studies for this discussion was published in The Journal of Urology.
Researchers examined men receiving testosterone therapy and compared those who developed a hematocrit of at least 52% with those who did not.
After matching the groups, major adverse cardiovascular events or venous thromboembolism occurred in:
5.15% of men who developed polycythemia
versus
3.87% of men who did not.
The odds ratio was 1.35.
The elevated-hematocrit group also demonstrated higher odds of myocardial infarction and venous thromboembolism.
Importantly, however, this was an observational database study.
It shows an association.
It cannot definitively prove that a hematocrit of 52% directly caused those events.
The patients developing erythrocytosis may differ from other men in ways that contribute to cardiovascular risk despite attempts to control statistically for those differences.
Nevertheless, I would not dismiss this study.
It gives clinicians another reason to take a rising hematocrit seriously rather than waiting indefinitely for it to become severely elevated.
Why Do You Keep Hearing the Number 54%?
Because major professional guidelines have traditionally used approximately 54% as an important intervention threshold.
The American Urological Association recommends checking hemoglobin and hematocrit before starting testosterone.
If baseline hematocrit exceeds 50%, the AUA recommends considering withholding testosterone until the reason for the elevation has been evaluated.
During treatment:
A hematocrit ≥54% warrants intervention.
Management may include reducing testosterone exposure, evaluating free testosterone and SHBG where appropriate, and investigating other causes of erythrocytosis.
The Endocrine Society similarly recommends monitoring hematocrit after starting testosterone and intervening when significant erythrocytosis develops. Its guideline also uses 54% as an important threshold and recommends withholding testosterone until hematocrit returns to an acceptable range before restarting at a lower dose.
But remember:
54% is not a magical biological cliff.
A hematocrit of 53.9% isn’t harmless while 54.1% suddenly becomes dangerous.
Risk exists on a continuum.
Clinical context matters.
My Concern Starts Before 54%
If someone’s hematocrit progresses:
46 → 48 → 50 → 52 → 53.5%
I don’t think the appropriate strategy is simply:
“You’re below 54. See you next year.”
The trend itself contains information.
I want to know why it is rising.
That is one of the major advantages of longitudinal men’s-health care.
We aren’t treating individual laboratory numbers.
We are watching physiology evolve over time.
Before Blaming Testosterone, Look for Other Causes
An elevated hematocrit on TRT does not automatically mean testosterone is the only cause.
Several other conditions can increase red blood cell production.
Obstructive sleep apnea
This is one of the first things I consider.
Intermittent nighttime hypoxia can stimulate erythropoietin and increase red-cell production.
And sleep apnea is extremely common among the same middle-aged male population receiving testosterone therapy.
Untreated sleep apnea plus testosterone can be a particularly important combination to recognize.
Smoking
Smoking can increase carboxyhemoglobin and contribute to secondary erythrocytosis.
Chronic lung disease or hypoxia
COPD and other conditions affecting oxygenation can contribute.
Altitude
Someone living at significant elevation may naturally have a higher hematocrit than someone living near sea level.
Dehydration
This is different.
Dehydration reduces plasma volume and can make the hematocrit appear elevated without actually producing additional red blood cells.
That is sometimes called relative erythrocytosis or hemoconcentration.
One unexpectedly elevated CBC should therefore be interpreted in context.
Primary hematologic disease
Occasionally an elevated hematocrit is not caused by TRT at all.
Persistent or unexplained erythrocytosis may require hematologic evaluation.
The AUA specifically recommends additional evaluation when hematocrit remains elevated despite appropriately managed testosterone levels.
Testosterone Dose and Formulation Matter
All testosterone therapies are not identical when it comes to hematocrit.
Injectable testosterone appears to produce some of the largest increases in hemoglobin and hematocrit.
The AUA notes that injectable preparations have demonstrated greater increases than transdermal preparations in clinical trials, likely in part because injections can produce relatively high testosterone concentrations after administration. These studies often used more outdated protocols, however.
This is one reason I care about more than simply the weekly milligram number.
I want to know:
What is the dose?
How often is it being given?
What does the testosterone level look like?
When was the laboratory test drawn relative to the injection?
What is the free testosterone?
What is the SHBG?
Are testosterone concentrations repeatedly supraphysiologic?
How rapidly is the hematocrit rising?
Simply prescribing testosterone and checking a total testosterone once a year misses much of the story.
Does Splitting Testosterone Injections Help?
Sometimes changing the dosing strategy can make physiologic sense.
Large intermittent injections can create higher peaks followed by lower troughs.
Reducing the total testosterone exposure or changing the formulation can reduce erythrocytosis in some patients.
What I would not do is promise every man that simply changing from one weekly injection to multiple tiny injections will automatically fix his hematocrit.
Individual responses vary, and the strongest evidence supports adjusting overall testosterone exposure and/or formulation rather than assuming one injection frequency solves every case.
Should Everyone With a High Hematocrit Donate Blood?
This is another area where TRT management sometimes becomes too simplistic.
The old approach is:
Hematocrit high? Donate blood.
Then three months later:
High again? Donate again.
And repeat indefinitely.
Therapeutic phlebotomy absolutely can lower hematocrit.
But that does not mean recurrent phlebotomy should be used to compensate forever for an unnecessarily aggressive testosterone regimen.
Repeated blood removal can eventually reduce iron stores.
A 2024 review specifically questioned whether routine repeated phlebotomy for testosterone-induced erythrocytosis is as evidence-based as many assume. The authors note that direct evidence establishing the long-term safety and benefit of repetitive phlebotomy in this setting is limited and raise concerns about iron depletion and its biological consequences.
That does not mean phlebotomy should never be used.
It means:
Fix the underlying problem too.
If someone’s testosterone dose repeatedly drives his hematocrit excessively high, routinely removing blood while continuing the same regimen may not be the best long-term strategy.
What I Do When Hematocrit Starts Rising
The exact decision depends on the patient, but conceptually I work through several questions.
1. Confirm the value
Was the patient dehydrated?
Is this a new finding?
What have the previous CBC values shown?
2. Look at the trajectory
A hematocrit that has been stable at 49% for years is different from one that moved from 45% to 53% shortly after changing testosterone therapy.
3. Evaluate the testosterone regimen
Is the dose excessive?
Are testosterone concentrations supraphysiologic?
What are total testosterone, free testosterone and SHBG showing?
4. Look for contributing factors
Especially:
Sleep apnea
Smoking
Hypoxia
Pulmonary disease
Altitude
Dehydration
5. Modify treatment when appropriate
Options may include:
Reducing testosterone dose
Changing the testosterone formulation
Adjusting the treatment regimen
Temporarily holding therapy at substantially elevated levels
Treating contributing medical conditions
6. Use phlebotomy selectively
Blood donation or therapeutic phlebotomy can be useful when clinically appropriate, but it should not automatically replace thoughtful testosterone management.
7. Investigate unusual or persistent erythrocytosis
If the degree of erythrocytosis seems disproportionate to the testosterone exposure—or persists despite correcting it—the patient may need further evaluation, sometimes including hematology.
What About Aspirin?
Another common question is:
“My hematocrit is high. Should I start taking aspirin?”
I would not automatically start aspirin solely because someone taking testosterone has a mildly elevated hematocrit.
Aspirin has its own potential risks, particularly bleeding.
The better approach is to identify why the hematocrit is elevated and manage the underlying driver rather than assuming aspirin neutralizes the problem.
Whether aspirin is appropriate should depend on the individual’s broader cardiovascular and medical situation—not simply the fact that he takes testosterone.
When Should Hematocrit Be Checked?
At Fit and Fine Health, a CBC is part of appropriate baseline and follow-up testosterone monitoring.
The Endocrine Society recommends hematocrit measurement at baseline, again approximately 3–6 months after initiation, and then ongoing monitoring thereafter.
Monitoring may need to occur more frequently when:
Testosterone doses are changing
Hematocrit is already trending upward
The patient previously developed erythrocytosis
Sleep apnea or hypoxia is present
Other medical risk factors exist
A man on long-term TRT should know his hematocrit just as readily as he knows his testosterone level.
So Does “Thick Blood” From TRT Cause Blood Clots?
Here is the best evidence-based answer:
Not automatically.
Testosterone can increase red blood cell production.
Increasing hematocrit increases blood viscosity.
Properly monitored testosterone therapy has not consistently been shown in randomized studies to dramatically increase venous thromboembolism.
But observational evidence suggests men on testosterone who develop significant erythrocytosis—particularly around or above a hematocrit of 52%—may experience greater cardiovascular and thromboembolic risk than men whose hematocrit remains controlled.
That means the correct response is neither:
“Hematocrit doesn’t matter.”
Nor:
“Your hematocrit is 52%, so you’re about to have a blood clot.”
The correct response is:
Monitor it. Understand why it is happening. Correct modifiable causes. Optimize the testosterone regimen. And intervene before a manageable laboratory change becomes an avoidable problem.
Good TRT Management Is More Than Writing Testosterone
Anyone with a prescribing license can write a prescription.
Managing testosterone well requires much more.
You need to understand:
Testosterone pharmacology
Total and free testosterone
SHBG
Estradiol
PSA
Fertility
Cardiometabolic risk
Sleep apnea
Hemoglobin and hematocrit
And how all of those variables interact over years of treatment
Hematocrit is a perfect example.
The answer isn’t automatically stopping testosterone.
It isn’t automatically donating blood.
And it certainly isn’t ignoring the laboratory abnormality.
It is understanding the physiology and managing the patient in front of you.
Concerned About Your Hematocrit—or Your Current TRT Program?
If you’re currently receiving testosterone and have been told your hematocrit is too high, Fit and Fine Health can review more than just one number.
We evaluate your testosterone regimen, total and free testosterone, SHBG, CBC, cardiovascular and metabolic risk factors, sleep history and the rest of the clinical picture to determine what may actually be driving the change.
We can also arrange comprehensive men’s-health laboratory testing through our laboratory partners if you need updated testing before your consultation.
The goal isn’t simply to get a testosterone level into range.
The goal is to manage testosterone safely, intelligently and longitudinally.
Fit and Fine Health
Physician-led men’s health, hormone optimization, metabolic health and sexual health.
David Hall, MD, CWC
Board-Certified Urologist
Certified Wellness Coach | Personal Trainer
This article is for educational purposes and does not replace individualized medical evaluation or treatment. Seek urgent medical attention for symptoms concerning for a blood clot, including sudden shortness of breath, chest pain, coughing blood, or new unilateral leg swelling or pain.